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Background: Fluticasone furoate (FF)/vilanterol (VI) is a once-daily maintenance treatment for asthma
and chronic obstructive pulmonary disease. The duration of bronchodilation beyond 24 h has not been
determined previously.
Methods: Adults aged 18e65 (n ¼ 32), with asthma and reversibility to salbutamol (15% and 200 mL
increase in forced expiratory volume in 1 s [FEV1]) participated in a double-blind, placebo-controlled,
crossover study. Patients were admitted to a clinical trials unit for 72 h, and inhaled, in random order,
placebo or FF/VI 100/25 mcg via ELLIPTA dry powder inhaler on two occasions 7e14 days apart. FEV1 was
measured at baseline, 15 and 30 min, 1, 2, 4, 12, 24, 36, 48, 60, and 72 h. The differences in change in FEV1
from baseline between treatments and corresponding two-sided 95% conﬁdence intervals (CI) were
calculated at each time point.
Findings: FF/VI produced a rapid onset of bronchodilation (adjusted mean difference in change from
baseline in FEV1 versus placebo at 15 min, 252 mL [95% CI 182e322]). Maximum bronchodilation was
observed at 12 h (adjusted mean difference in the change from baseline in FEV1, 383 mL [95% CI 285
e481]). Bronchodilation was maintained throughout the 72-h assessment period (adjusted mean dif-
ference in the change in FEV1 from baseline at 72 h, 108 mL (95% CI 15e200]). FF/VI was well tolerated
and no serious side effects were reported.
Interpretation: A single dose of FF/VI 100/25 mcg showed evidence of a 72-h bronchodilator duration of
action in adults with asthma.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
International asthma guidelines recommend the use of combi-
nation inhaled corticosteroid (ICS)/long-acting b2 agonist (LABA)
therapy as the preferred maintenance treatment in moderate to
severe asthma [1]. However, current ICS/LABA products require
twice-daily dosing and treatment adherence represents a potentialof New Zealand, PO Box 7902,
Braithwaite).
Ltd. This is an open access article uproblem [2e5]. This has led to the development of the next gen-
eration of inhaled LABA and corticosteroid medications with a
longer duration of action to enable once-daily dosing, with the
potential to improve patient convenience and enhance compliance
[4e6].
Vilanterol trifenatate (VI) is a member of the next generation of
LABAswith at least a 24-h duration of bronchodilator action [7e10].
In-vitro studies have shown it to bemore potent and to have greater
intrinsic activity than salmeterol, with a similar selectivity proﬁle
for the b2-adrenoceptor (AR) over both the b1-and b3-AR subtypes
compared with salbutamol, and superior to the other b-agonistsnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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duration of action than salmeterol, exhibiting signiﬁcant bron-
chodilation 22 h after treatment [7]. Fluticasone furoate (FF) is a
novel glucocorticoid that has enhanced afﬁnity for the glucocorti-
coid receptor, with fast association and slow dissociation [11].
These properties result in a longer duration of action and prolonged
retention in the lung, compared with ﬂuticasone propionate (FP),
and have enabled its use as a once-daily medication in asthma
[12e15].
The combination FF/VI inhaler (Relvar/Breo ELLIPTA®; ELLIPTA®
is a trademark of the GSK group of companies) is efﬁcacious as a
once-daily treatment in asthma [16e18] and COPD [19e23]. The
bronchodilator effects of FF/VI are well characterised up to 24 h in
patients with asthma [17,18] and COPD [19,21e23]. However, there
is still signiﬁcant bronchodilation at 24 h [1723] and persistence
of bronchodilation beyond this dosing interval time point has not
been determined. The aim of this study was to investigate the
duration of the bronchodilator effect over a 72-h period following a
single dose of the combination FF/VI 100/25 mcg inhaler adminis-
tered in the morning in adult patients with asthma. The secondary
objective was to investigate the onset of bronchodilation.
2. Methods
2.1. Patients
Volunteers for this study were recruited from the Medical
Research Institute of New Zealand database of asthma volunteers
and local newspaper advertising. The ﬁrst patient was screened in
October 2013 and the last patient completed the study in
September 2014. Adults aged 18e65 years with a diagnosis of
asthma by a doctor were eligible for inclusion if at screening they
demonstrated a pre-bronchodilator predicted forced expiratory
volume in 1 s (FEV1) 60%, an increase 15% over baseline and an
absolute change of 200 mL within 30 min following four in-
halations of salbutamol 100 mcg via metered dose inhaler through
a spacer device. Patients were required to be on an ICS for at least 12
weeks prior to screening and be clinically stable on a daily dose of
ICS (FP 100e500 mcg or equivalent), with or without a short-acting
b2-agonist (SABA) for 4 weeks prior to the screening visit. Patients
were also required to be able to replace their current asthma
treatments with a SABA inhaler from 7 days prior to randomisation
until study completion and withhold their SABA for at least 6 h
prior to study visits. Important exclusion criteria included a history
of life-threatening asthma, current smoker or a pack year history of
10 years, other signiﬁcant pulmonary diseases, respiratory
infection within 1 month of entry to the study, any asthma exac-
erbation that required oral corticosteroids or that resulted in hos-
pitalisationwithin 12 weeks of screening, LABA use in the 12 weeks
prior to screening, or a signiﬁcant electrocardiograph abnormality.
More detailed inclusion and exclusion criteria can be found in a
summary of the protocol at http://www.gsk-clinicalstudyregister.
com/study/116592?study_ids¼116592#ps.
2.2. Study design
This was a randomised, double-blind, placebo-controlled, cross-
over study (Clinicaltrials.gov ID: NCT01837316; Supplementary
Fig. S1). Patients were admitted to the Clinical Trials Unit (CTU) at
Wellington Regional Hospital for 72 h on two occasions to receive
the randomised treatments, FF/VI 100/25 mcg inhalation powder
administered via the ELLIPTA dry powder inhaler (DPI) and placebo
(ﬁrst strip lactose, second strip lactose, and magnesium stearate)
administered via the ELLIPTA DPI.
Within 21 days of the screening visit, eligible patients attendedon Day 1 of the treatment period. Spirometry was undertaken at
baseline (pre-medication) and then at 15 and 30 min, 1, 2, 4, 12, 24,
36, 48, 60, and 72 h post-medication administration. Spirometry
was performed using a body plethysmograph (Masterscreen Body,
Erich-Jaeger, Friedberg, Germany). The highest value of three
technically acceptable manoeuvres was retained as per American
Thoracic Society/European Respiratory Society guidelines [24].
Between 7 and 14 days later, patients returned to the clinic for
treatment period 2 and the procedures were repeated with
whichever study medication they had not already received
(Supplementary Fig. S1). Patients attended again within 10 days for
a ﬁnal follow-up assessment.
Maintenance ICS was stopped 24 h prior to study medication
dosing until 72 h after dosing. Smoking and caffeine or xanthine-
containing products were forbidden for 8 h prior to the study
medication administration until completion of the 72-h
assessments.
Patients were required to avoid SABA use as a rescue medication
for 8 h prior to screening. Patients were also requested to avoid
SABA use during the 72-h study periods in the CTU unless abso-
lutely necessary and, if possible, not within 8 h of the next lung
function assessment. SABA use was recorded, and if used within 8 h
prior to any lung function assessment, the data from that time point
were excluded from the analysis.
2.3. Randomisation and masking
Patients were assigned to one of two treatment sequences (AB
or BA, where A was placebo and B was FF/VI 100/25 mcg) in
accordance with the randomisation schedule, which was generated
by the study statistician prior to the start of the study, using vali-
dated internal software. The investigators and patients were blin-
ded to the treatment assignments.
2.4. Sample size
The sample size was based on feasibility, with some justiﬁcation
derived from a previous study in this subject population, in which
the standard deviation (SD) of the paired difference in FEV1 be-
tween a combination ICS/LABAmedication and placebowas 190mL
[25]. This was used to obtain an estimate of within subject SD to
assess the width of the conﬁdence interval (CI) for the difference
between treatments based on the proposed sample size of 32 pa-
tients. Based on the within patient SD of 270 mL and a sample size
of 32 patients, this equates to a half width of a 95% CI of 138mL. This
calculation is based on a symmetric two-tailed procedure and a
type I error rate of 5%.
2.5. Statistical methods
The primary objective of the study was to estimate the bron-
chodilator effect over 72 h following a single dose of FF/VI 100/25
mcg compared with placebo. Changes from baseline in FEV1 at time
points 15, 30 min, 1, 2, 4, 12, 24, 36, 48, 60, and 72 h post dose were
the main endpoints. Baseline was deﬁned as Day 1 pre-dose mea-
surement for FEV1 for each treatment period. A mixed effects
repeated measures analysis of covariance model was ﬁtted, with
ﬁxed effect terms for treatment, period, time, time by treatment
interaction, patient baseline, period baseline, sex, and age ﬁtted as
covariates, with subject as a random effect. From these analyses,
point estimates and their associated 95% CIs were constructed for
each treatment at each time point and the difference between
adjusted means and the corresponding two-sided 95% CI was
calculated at each time point. In a post-hoc assessment, the
adjusted mean change in FEV1 from baseline following FF/VI, and
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the bronchodilation, deﬁned as change from baseline of 200 mL or
greater.
The secondary endpoint, time to onset of bronchodilator effect
(deﬁned as the time point when FEV1 ﬁrst met or exceeded 12% and
200 mL over baseline during the 0e4 h serial measurements), was
described by a frequency table showing how many patients ach-
ieved onset in the ﬁrst 4 h, median times of the event and a Kaplan-
Meier plot showing the cumulative incidence curves for each
treatment.
Safety data were presented in tabular and/or graphical format
and summarised descriptively according to GSK's Integrated Data
Standards Library (IDSL) standards. The study was registered with
clinicaltrials.gov (NCT01837316) and was approved by the New
Zealand Health and Disability Ethics Committee (13/CEN/70). All
patients provided written informed consent prior to undertaking
any study-related procedures.
The statistical analyses were conducted using SAS version 9.3.
3. Results
The baseline characteristics of the 32 randomised patients are
shown in Table 1. Patients had moderately severe asthma with a
mean pre-bronchodilator FEV1 of 79% predicted and marked
bronchodilator reversibility with a mean increase in FEV1 after
bronchodilator of 21%. One patient withdrew consent 4 h after
receiving FF/VI during the ﬁrst treatment period, and one was
withdrawn by the investigators due toworsening asthma 48 h after
receiving placebo during the second treatment period (Fig. 1). On
nine occasions in patients receiving placebo treatment, rescue
SABA was used within 8 h of the next FEV1 measurement and for
this reason the FEV1 measurement was excluded from the analyses.
3.1. Efﬁcacy
3.1.1. Main endpoints (Tables 2 and 3, Figs. 2 and 3, Supplementary
Tables S1, S2)
FF/VI 100/25 mcg was associated with a rapid onset of bron-
chodilation with an increase in adjusted mean FEV1 change from
baseline compared with placebo of 252 mL (95% CI 182e322) after
15 min, the ﬁrst post-dose time point assessment (Table 2, Fig. 2).
Higher FEV1 values were observed in patients receiving FF/VI versus
placebo throughout the 72-h post-dose assessment period, result-
ing in an adjusted mean difference in FEV1 change from baseline of
108 mL (95% CI 15e200) compared with placebo at 72 h. The
maximum bronchodilation was seen at the 12-h post-dose time
point, with an adjusted mean difference in FEV1 change from
baseline of 383 mL (95% CI 285e481) compared with placebo
(Table 3, Fig. 3). The difference in FEV1 change from baseline be-
tween FF/VI and placebo progressively reduced from this time
point. At the 48-h time point, the adjusted mean difference in FEV1Table 1
Characteristics of randomised participants (n ¼ 32).
Characteristic
Age (years)
BMI (kg/m2)
ICS dose (mcg/day)a
Pre-bronchodilator FEV1 (% predicted)
Post-bronchodilator FEV1 reversibility (% change from baseline)
Screening FEV1 (L)
Sex (female)
BMI, body mass index; FEV1, forced expiratory volume in 1 s; FP, ﬂuticasone prop
a ICS dose: FP mcg/day or equivalent.change from baselinewas 200mL (95% CI 101e299) comparedwith
placebo. For FF/VI the mean change from baseline at 48 h was
268 mL (95% CI 194e342) (Table 2, Fig. 2).
3.1.2. Secondary endpoints (Supplementary Tables S3, S4)
More patients achieved ‘onset of bronchodilator effect’ (deﬁned
as an increase in FEV1 of >12% or 200 mL) within the ﬁrst 4 h
following FF/VI 100/25 mcg treatment, 21/32 (66%), compared with
placebo treatment, 5/31 (16%) (Supplementary Table S3).
Use of SABA rescue medication during the 72-h treatment
period was higher following administration of placebo than
following FF/VI (Supplementary Table S4). Following placebo, 15/31
(48%) patients took rescue SABA on at least one occasion, with 13/
31 (42%) taking it on two or more occasions (Supplementary
Table S4). Following FF/VI, 2/32 (6%) patients took rescue SABA on
one occasion, with none taking it on two or more occasions.
3.1.3. Safety results (Supplementary Tables S5, S6)
No serious adverse events (SAEs) were reported during the
study. The incidence of adverse events (AEs) was high in both study
groups (72% [FF/VI] and 81% [placebo]; Supplementary Table S5).
The most frequently reported AEs (2 events in any treatment
group) were headache (19 patients) and asthma (10 patients).
Asthma, chest discomfort, and wheezing were all reported more
frequently on placebo compared with FF/VI. Back pain was more
frequent following FF/VI treatment compared with placebo (6% [FF/
VI] and 3% [placebo]). All other AEs were only reported by one or
two patients on either placebo, FF/VI, or both treatments. Overall,
there were similar or lower incidences of AEs following FF/VI
administration compared with placebo. Headache was the most
common drug-related AE with similar incidence between treat-
ments, occurring in 8 (25%) patients receiving FF/V versus 7 (23%)
patients receiving placebo (Supplementary Table S6). An episode of
asymptomatic sinus tachycardia was recorded in one patient 72 h
after FF/VI dosing.
4. Discussion
This randomised, double-blind, placebo-controlled trial
demonstrated that a single dose of FF/VI 100/25 mcg has a bron-
chodilator duration of action of at least 72 h in adults with asthma.
The combination FF/VI resulted in a rapid onset of bronchodilation,
with a maximum bronchodilator effect at 12 h versus placebo.
To our knowledge, this is the ﬁrst study demonstrating that the
bronchodilator duration of action of a LABA (either alone or in an
ICS/LABA combination) lasts beyond 36 h [26]. The maximum
bronchodilation was achieved at the 12-h time point (adjusted
mean difference in FEV1 from placebo: 383 mL [95% CI 285e481]),
which is the normal dosing interval for twice-daily LABAs such as
salmeterol and formoterol fumarate. This magnitude of broncho-
dilation was maintained through to the 24-h time point (adjustedMean (SD) Minimumemaximum
38.5 (12.26) 18e64
27.3 (4.28) 19.7e34.7
248 (133) 100e500
78.7 (11.4) 59.9e101.0
20.9 (6.26) 15.1e46.5
2.98 (0.84) 1.78e5.09
n (%)
13 (41)
ionate; ICS, inhaled corticosteroid; SD, standard deviation.
Fig. 1. Treatment ﬂow.
Table 2
Change from baseline FEV1 (mL) 0e72 h after administration of FF/VI 100/25 mcg and placebo.
Treatment N Planned relative time (h) n Adjusted mean change in FEV1 (mL) 95% CI of adjusted mean change
Placebo 31 0.25 31 17 40e74
0.5 31 8 48e65
1 31 74 11e137
2 31 131 65e196
4 31 85 16e154
12 29 56 131e19
24 30 32 34e98
36 29 61 1e122
48 31 67 7e142
60 28 64 8e137
72 28 117 46e187
FF/VI 100/25 mcg 32 0.25 32 269 213e325
0.5 31 313 257e368
1 32 345 282e407
2 32 428 364e493
4 32 420 352e488
12 31 327 254e401
24 31 376 311e441
36 31 298 238e358
48 31 268 194e342
60 31 196 126e267
72 31 225 156e293
CI, conﬁdence interval; FEV1, forced expiratory volume in 1 s; FF, ﬂuticasone furoate; VI, vilanterol.
The scheduled FEV1 reading was not performed in one patient in period 1 at 0.5 h.
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which is the normal dosing interval for FF/VI. At the ﬁnal 72-h time
point, bronchodilation produced by FF/VI was still apparent with an
adjusted mean difference from placebo in FEV1 of 108 mL (95% CI
15e200). By comparison, we and others have previously shown
that under similar controlled conditions the LABAs salmeterol and
formoterol, either administered separately or as salmeterol/FP or
formoterol/budesonide combination inhalers, have bronchodilator
durations of action of up to 24 h [25,27e29].
Although FF/VI 100/25 was shown to have a bronchodilator
duration of action of up to 72 h, the extent of this effect at the later
time-points was probably belowwhat would be considered to be of
clinical signiﬁcance. Assessment of the minimally clinically
important increase in FEV1 requires determination of change frombaseline following treatment administration rather than the
treatment difference compared with placebo. The minimal clini-
cally important difference in FEV1 has not been rigorously estab-
lished for asthma. Although in a validation study [30], the average
minimal perceivable improvement in FEV1 (change from baseline)
of 230mL corresponded to a reduction of inhaled SABA of 0.81 puffs
per day. The correspondingmeasure for moderate improvement for
FEV1 response and associated reduction in SABA use were 250 mL
and 1.47 puffs per day, respectively [30]. An increase in FEV1 of
200 mL compared with baseline during a single testing session
suggests a ‘‘signiﬁcant’’ bronchodilation [31], and is used to
demonstrate an individual's responsiveness to a bronchodilator.
Based on a limit of 200 mL, the duration of bronchodilation (as
change from baseline) produced by FF/VI 100/25 mcg was longer
Fig. 2. Adjusted mean FEV1 (mL; change from baseline) and 95% CIs 0e72 h after administration of FF/VI 100/25 (n ¼ 32) and placebo (n ¼ 31) in patients with asthma.
Table 3
Adjusted mean differences in FEV1: FF/VI 100/25 mcg minus placebo from 0.25 to
72 h.
Planned relative time (h) FF/VI minus placebo adjusteda
mean difference FEV1 (mL) (95% CI)
0.25 252 (182e322)
0.5 304 (235e374)
1 271 (190e351)
2 298 (214e382)
4 335 (245e424)
12 383 (285e481)
24 344 (258e429)
36 237 (159e316)
48 200 (101e299)
60 132 (38e227)
72 108 (15e200)
CI, conﬁdence interval; FEV1, forced expiratory volume in 1 s; FF, ﬂuticasone furoate;
VI, vilanterol.
a Adjusted for treatment, period, time, time by treatment interaction, subject
baseline, period baseline, sex and age.
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48 h time point. As a result, we propose that the duration of clin-
ically relevant bronchodilation produced by single dose FF/VI 100/
25 mcg is in the region of at least 48 h.
No new safety concerns were identiﬁed, although as a single-
dose study, it was not designed to assess safety. No SAEs were re-
ported during the study and themost frequently reported AEs were
headache (19 patients) and asthma (10 patients) in total. The
number of patients with drug-related AEs was similar between
groups.
There are a number of methodological issues relevant to the
interpretation of this study. Firstly, participants were admitted to a
CTU for the 72-h study period to provide a controlled environment
to avoid provoked bronchoconstriction secondary to everyday ex-
posures such as exercise and cold air. This also ensured that pa-
tients did not take caffeine-containing products and that SABA use
for relief of asthma symptoms was fully documented by the in-
vestigators. If participants experienced worsening asthma to the
extent that they required rescue SABA medication, the investigator
supervised and documented the administration of salbutamol via ametered dose inhaler, preferably after a lung function measure-
ment. If rescue salbutamol was administered within 8 h of the next
lung function measurement, the FEV1 at that time point was not
included in the analysis. In the event, there were only nine occa-
sions in ﬁve patients when rescue salbutamol was administered
within 8 h of the next lung function measurement, all of these were
following placebo administration, and so such rescue bronchodi-
lator use is unlikely to have inﬂuenced the results reported here.
Patients were required to demonstrate bronchodilator revers-
ibility at screening, with an increase in FEV1 of 15% and an ab-
solute change of 200 mL from baseline within 30 min following
400 mcg of salbutamol. This criterion enabled inclusion of suitable
patients to ensure that both the onset and duration of bronchodi-
lation could be assessed. LABA use in the last 3 months prior to
study entry was an exclusion criterion that ensured participants
were LABA free. However, we acknowledge that these criteria
resulted in the exclusion of a proportion of patients withmoderate-
to-severe asthma in whom ICS/LABA therapy is indicated, thereby
reducing the generalisability of the study ﬁndings. Patients were all
taking maintenance ICS prior to randomised treatment adminis-
tration, suggesting that the observed bronchodilator response is
likely to have been due mainly to the VI component.
VI was administered in the combination FF/VI ELLIPTA DPI, as
this is the formulation inwhich VI will be available for use in adults
with asthma; there is no separate VI inhaler product available for
use in adults with asthma, thereby avoiding possible LABA mono-
therapy, if ICS and LABA therapy is prescribed as separate inhalers
[32]. Although both the FF/VI 100/25 mcg and 200/25 mcg prepa-
rations are the once-daily doses recommended in asthma, based on
the clinical trials in which efﬁcacy has been demonstrated [16e18],
we examined the FF/VI 100/25 mcg preparation as this is the dose
likely to be most commonly used in clinical practice. However the
results are likely to be generalisable to the FF/VI 200/25 mcg
preparation, as it contains the same VI dose. Placebo was admin-
istered as a control treatment, due to the signiﬁcant placebo
bronchodilator response in asthma [8,10] and the circadian varia-
tion in lung function in asthma [33].
FF/VI was administered in the morning to enable the onset of
action to be determined with ﬁve measurements of lung function
within the initial 4 h period, which would have been difﬁcult if
Fig. 3. Adjusted mean FEV1 (mL, change from baseline) treatment differences and 95% CIs 0e72 h after administration of FF/VI 100/25 (n ¼ 32) and placebo (n ¼ 31) in patients with
asthma.
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there is no difference in bronchodilator response to FF/VI with
morning or evening dosing [34], and the study results are consid-
ered generalisable to afternoon dosing.
The rapid onset and prolonged bronchodilator duration of ac-
tion of FF/VI is consistent with its known pharmacological prop-
erties in vitro. In human airways, VI has been shown to have a faster
onset and longer duration of action than salmeterol [7]. It would be
interesting to now determine the duration of action of other LABAs
such as indacaterol, abediterol, and olodaterol, which are also
recommended for once-daily use in asthma.
There are twomain clinical implications of the ﬁndings reported
here. Firstly, the study conﬁrmed that the bronchodilator duration
of action of FF/VI is sufﬁcient to enable once-daily dosing in asthma.
Secondly, it suggests that if a patient inadvertently missed a daily
dose, then FF/VI may have sufﬁcient bronchodilator effect for a
further 24-h period.
In conclusion, a single dose of FF/VI 100/25 mcg showed evi-
dence of a 72-h bronchodilator duration of action in adults with
asthma. The duration of clinically relevant bronchodilation pro-
duced by this dose of FF/VI was at least 48 h.Contributors
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